Camurus
676.5 SEK +4.08%7 investors are following this company
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Revenue
-
EBIT %
-
P/E
86.95
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CAMX
Daily low / high price
598 / 679.5
SEK
Market cap
39.67B SEK
Turnover
100.28M SEK
Volume
153K
Latest videos
Financial calendar
Interim report
16.07.2024
Interim report
07.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sandberg Development AB | 38.0 % | 38.0 % |
Fjärde AP-fonden | 4.5 % | 4.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Camurus AB: Camurus' Interim Report Second Quarter 2024
Camurus AB: Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools